Cited by 317Breast Cancer Treatment StudiesAdvanced Breast Cancer TherapiesEstrogen and related hormone effects

The DOI matches its Crossref record; 106 of the 106 references it cites were found in a registry or an index.

Systemic Therapy for Estrogen Receptor–Positive, HER2-Negative Breast Cancer

Burstein, Harold J.·2020·New England Journal of Medicine

Open this paper in CoChat — free account

Abstract

ER-positive, HER2-negative breast cancer, which accounts for about 70% of all breast cancers, is heterogeneous. Antiestrogen therapy is the cornerstone of systemic therapy, and its efficacy depends on such factors as grade, Ki-67 labeling, and progesterone receptor expression.

Integrity signals

Registry

Crossref · 10.1056/nejmra1307118

Cites

106 of 106 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Comprehensive molecular portraits of human breast tumours
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11412 · Cited by 12,129
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
Robson, M., Im, S.-A., Senkus, E., Xu, B., Domchek, S. M., Masuda, N., Delaloge, S., Li, W., Tung, N., Armstrong, A., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1706450 · Cited by 3,294
Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials
Early Breast Cancer Trialists' Collaborative Group (EBCTCG) (2011) · The Lancet · doi:10.1016/s0140-6736(11)60993-8 · Cited by 3,075
Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
Baselga, J., Campone, M., Piccart, M., Burris, H. A., Rugo, H. S., Sahmoud, T., Noguchi, S., Gnant, M., Pritchard, K. I., Lebrun, F., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1109653 · Cited by 2,863
Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes
von Minckwitz, G., Untch, M., Blohmer, J.-U., Costa, S. D., Eidtmann, H., Fasching, P. A., Gerber, B., Eiermann, W., Hilfrich, J., Huober, J., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.8595 · Cited by 2,659
Alpelisib for PIK3CA -Mutated, Hormone Receptor–Positive Advanced Breast Cancer
André, F., Ciruelos, E., Rubovszky, G., Campone, M., Loibl, S., Rugo, H. S., Iwata, H., Conte, P., Mayer, I. A., Kaufman, B., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1813904 · Cited by 2,622
Gene Expression and Benefit of Chemotherapy in Women With Node-Negative, Estrogen Receptor–Positive Breast Cancer
Paik, S., Tang, G., Shak, S., Kim, C., Baker, J. B., Kim, W., Cronin, M. T., Baehner, F. L., Watson, D., Bryant, J., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.7985 · Cited by 2,597
Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer
Sparano, J. A., Gray, R. J., Makower, D. F., Pritchard, K. I., Albain, K. S., Hayes, D. F., Geyer, C. E., Dees, E. C., Goetz, M. P., Olson, J. A., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1804710 · Cited by 2,397
Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation
Litton, J. K., Rugo, H. S., Ettl, J., Hurvitz, S. A., Gonçalves, A., Lee, K.-H., Fehrenbacher, L., Yerushalmi, R., Mina, L. A., Martin, M., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1802905 · Cited by 2,175
Estrogen Receptor Status by Immunohistochemistry Is Superior to the Ligand-Binding Assay for Predicting Response to Adjuvant Endocrine Therapy in Breast Cancer
Harvey, J. M., Clark, G. M., Osborne, C. K., & Allred, D. C. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.5.1474 · Cited by 2,054

Show all 106 references

Research works printed but not linked: 2

Kalinsky K Barlow WE Meric-Bernstam F et al. First results from a phase III randomized clinical trial of standard adjuvant endocrine therapy (ET) +/- chemotherapy (CT) in patients (pts) with 1-3 positive nodes hormone receptor positive (HR+) and HER2-negative (HER2-) breast cancer (BC) with recurrence score (RS) <25: SWOGS1007 (RxPONDER). Presented at the virtual San Antonio Breast Cancer Symposium December 8–11 2020. abstract.
Mayer EL Gnant M DeMichele A et al. PALLAS: a randomized phase III trial of adjuvant palbociclib with endocrine therapy versus endocrine therapy alone for HR+/HER2- early breast cancer. Presented at the ESMO Virtual Congress September 20 2020. abstract. · DOI

Sorted by citations

Items 201–300 of 317

Excavating regulated cell death signatures to predict prognosis, tumor microenvironment and therapeutic response in HR+/HER2- breast cancer
Mao, S., Zhao, Y., Xiong, H., & Gong, C. (2024) · Translational Oncology · doi:10.1016/j.tranon.2024.102117 · Cited by 2
Knockdown of PVT1 inhibits cell proliferation in luminal and basal-like breast cancer subtypes by activating LATS2/Hippo signaling pathway
Zhang, H.-B., Zeng, Y., & Wang, G. (2025) · World Journal of Surgical Oncology · doi:10.1186/s12957-025-03944-6 · Cited by 2
Copy number heterogeneity identifies ER+ breast cancer patients that do not benefit from adjuvant endocrine therapy
van den Bosch, T., Rueda, O. M., Caldas, C., Vermeulen, L., & Miedema, D. M. (2022) · British Journal of Cancer · doi:10.1038/s41416-022-01906-3 · Cited by 2
Reply to Y. Kawamura et al
Loibl, S., Nekljudova, V., & Denkert, C. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.01403 · Cited by 2
Breast Cancer
De, S. K. (2022) · Wiley eBooks · doi:10.1002/9783527838561.ch6 · Cited by 2
Análise do grau histológico e marcadores imunohistoquímicos para a identificação de pacientes com câncer de mama luminal de alto risco
da Luz, F. A. C. (2022) · doi:10.14393/ufu.te.2022.272 · Cited by 2
Management of the axilla in postmenopausal patients with cN0 hormone receptor-positive/HER2-negative breast cancer treated with neoadjuvant endocrine therapy and its prognostic impact
García‐Tejedor, A., Falo, C., Fernández-González, S., Laplana, M., Gil‐Gil, M., Soler-Monsó, M. T., Pérez, E. M., Calvo, I., Calpelo, H., Bajén, M. T., et al. (2023) · Breast Cancer Research and Treatment · doi:10.1007/s10549-023-06926-y · Cited by 1
Adoption and use of immunotherapy in breast cancer management in Africa: barriers and prospect – a narrative review
Alani, J. M., Olaoye, D. Q., & Abdus-Salam, A. A. (2023) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000001398 · Cited by 1
Cost-effectiveness analysis of elacestrant versus standard endocrine therapy for second-/third-line treatment of patients with HR+/HER2- advanced or metastatic breast cancer: a US payer perspective
Zeng, W., Cao, X., Lin, J., Zheng, B., Li, N., Liu, M., & Cai, H. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1272586 · Cited by 1
Hesperitin Synergistically Promotes the Senescence Induction of Pentagamavunone-1 in Luminal Breast Cancer Cells, T47D
Rifai, F. N. P., Hanifa, M., Zulfin, U. M., Ikawati, M., & Meiyanto, E. (2024) · Journal of Tropical Biodiversity and Biotechnology · doi:10.22146/jtbb.88238 · Cited by 1
A Novel Compound from the Phenylsulfonylpiperazine Class: Evaluation of In Vitro Activity on Luminal Breast Cancer Cells
da Silva, F. C., Martinho, A. C. C., Ferreira, H. S. V., Siqueira, R. P., Arruda, V. M., Guerra, J. F. D. C., de Souza, M. L. D. R., Landin, E. S., Júnior, C. D. O. R., & Araújo, T. G. (2024) · Molecules · doi:10.3390/molecules29184471 · Cited by 1
Clinical impact of single-gene vs. panel sequencing in advanced HR + /HER2− breast cancer: insights and implications
Klocker, E. V., Dobrić, N., Graf, R., Beichler, C., Hlauschek, D., Suppan, C., Pancheri, L., Egle, D., Albertini, C., Bartsch, R., et al. (2025) · npj Breast Cancer · doi:10.1038/s41523-025-00805-z · Cited by 1
Unraveling the Potential of ctDNA in Precision Medicine for Breast Cancer
de Azevedo, J. C., da Silva, F. J., Rodrigues, A. S., de Sousa, S. B. M., da Silva, J. M. C., Ramos, I. B., Borges, B. D. N., Freitas, V. M., & Calcagno, D. Q. (2025) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-025-00800-x · Cited by 3
Causal associations between fibroblast growth factors and breast cancer: Evidence from 2-sample Mendelian randomization analysis
Feng, F., Sun, M., Yao, Y., Li, H., Song, L., & Sun, C. (2025) · Medicine · doi:10.1097/md.0000000000043876 · Cited by 1
XBP1s Mediates Cross‐resistance to Combination Treatment of CDK4/6 Inhibitors plus Endocrine Therapy in Breast Cancer
Sang, Y., Liu, S., Zhou, X., Chi, W., Xiong, M., Chen, M., Ren, H., Liu, D., Zhang, L.-Y., Xue, J., et al. (2025) · Advanced Science · doi:10.1002/advs.202409588 · Cited by 1
Restoration of chemosensitivity to drug resistant breast cancer cells through peptide activation of the anaphase promoting complex
VanGenderen, C. A., Harris, R. E., Mercier, G., Valentine, S., Lubachowski, M., Su, C., Davies, G. F., Arnason, T. G., & Harkness, T. A. A. (2026) · Scientific Reports · doi:10.1038/s41598-026-61328-6 · Cited by 1
Lessons From the SONIA Trial on Timing of CDK4/6 Inhibitors in Advanced Breast Cancer—The Sooner, the Better?
Valenza, C., & Burstein, H. J. (2026) · JAMA Oncology · doi:10.1001/jamaoncol.2025.6345 · Cited by 1
Self-citation
Current Landscape of Anti-HER2 Targeted Therapy in Breast Cancer: Challenges and Future Perspectives
Bharali, P., Mehta, V., Chand, S., & Chander, H. (2026) · Cancer Investigation · doi:10.1080/07357907.2026.2672753 · Cited by 1
TP53 mutation is associated with shorter treatment duration with CDK4/6 inhibitors, but not with immune checkpoint inhibitors, in ER-positive/HER2-negative breast cancer: real-world perspective
Oshi, M., Sugimori, M., Kawashima, K., Gandhi, S., Yamada, A., Narui, K., Ishikawa, T., Endo, I., & Takabe, K. (2026) · Breast Cancer Research · doi:10.1186/s13058-026-02305-9 · Cited by 1
ESR1 mutations in ER-positive breast cancer: from endocrine resistance to ctDNA-guided therapeutic interception
Martinez, T., Wegner, S., & Bahmad, H. F. (2026) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2026.1002375 · Cited by 1
Novel biomarkers in breast cancer for precision therapy and adaptive treatment strategies
Dai, D., & Micsik, T. (2026) · Advances in Translational Research · doi:10.1556/1661.2026.00016 · Cited by 4
Pyrazolo[4,3-H]quinazolines as Cyclin-dependent Kinase Inhibitors for Treating Cancer
De, S. K. (2023) · Current Medicinal Chemistry · doi:10.2174/0929867330666230525160458 · Cited by 1
(3,19)‐4‐Bromobenzylidene‐isoandrographolide Induces Apoptosis and Causes Loss of Mitochondrial Membrane Potential in MCF‐7 Breast Cancer Cells
Tamang, N., Inabathina, Y., Mavileti, S. K., Sripada, L., Nanduri, S., Golakoti, N. R., & Karanam, B. (2024) · ChemistrySelect · doi:10.1002/slct.202302498 · Cited by 1
Busting Breast Cancer Myths: A Deep Dive into Epidemiology, Risk Factors and Effective Management
Tamhane, K., & Jadhav, A. (2024) · International Journal of Innovative Science and Research Technology (IJISRT) · doi:10.38124/ijisrt/ijisrt24mar416 · Cited by 2
Retrospective registry of patients with locally advanced/metastatic HR+/HER2− breast cancer treated in clinical practice in Andalusia
Piudo, N. C., Blancas, I., González‐Flores, E., Henao, F., Álvarez, P. L., Pancorbo, D. M., Casado, S. G., Garrido, M. D. L. C. L., García, J. M. R., Guisado, A. M., et al. (2024) · Clinical & Translational Oncology · doi:10.1007/s12094-024-03510-8 · Cited by 1
Quantitative evaluation of the efficacy and safety profiles of two types of targeted inhibitors combined with endocrine therapy in ER+/HER2− metastatic breast cancer
Pan, M., Yan, L., Liu, Y., Xu, R., & Yang, J. (2024) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-024-03715-4 · Cited by 1
Drug discovery of N-methyl-pyrazole derivatives as potent selective estrogen receptor degrader (SERD) for the treatment of breast cancer
Dai, R., Bao, X., Liu, C., Yin, X., Zhu, Z., Zheng, Z., Wang, B., Yang, K., Wen, H., Li, W., et al. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116894 · Cited by 1
Increased risk of hypertrophic scarring in estrogen receptor-positive breast cancer: a bidirectional mendelian randomization study
Cao, Y., & Liu, C. (2025) · Archives of Dermatological Research · doi:10.1007/s00403-024-03737-z · Cited by 1
Angiotensin 1–7 and the Non-Peptide MAS-R Agonist AVE0991 Inhibit Breast Cancer Cell Migration and Invasion
Alfoudiry, M. M., & Khajah, M. A. (2025) · Biomedicines · doi:10.3390/biomedicines13030567 · Cited by 1
Transcriptional Control Leading to Clinical Outcomes in Breast Cancer Cases
Aftab, A., Khan, R., Hameed, U., Abbas, T., & Ahmad, B. (2022) · Springer eBooks · doi:10.1007/978-981-19-0197-3_13 · Cited by 1
Based on breast CEUS parameters combined with serum CA153, a nomogram model was constructed to predict the molecular classification of breastcancerPreprint
Ji, Y., Han, Z., Zhang, Y., & Sun, W. (2024) · medRxiv · doi:10.1101/2024.10.17.24315659 · Cited by 1
CLINICAL AND ECONOMIC ASPECTS OF HORMONOTHERAPY ER (+) HER2 (–) BREAST CANCER (BC): FOCUS ON AROMATASE INHIBITORS (AI)
Mishchenko, O. Y., Greshko, Y. I., Оstashko, V. F., & Berezniakov, A. (2021) · Likarska sprava · doi:10.31640/jvd.3-4.2021(12
A hierarchical approach to combine histological grade and immunohistochemical factors to identify high-risk luminal breast cancers
da Luz, F. A. C., Marinho, E. D. C., Nascimento, C. P., Marques, L. D. A., Delfino, P. F. R., Antonioli, R. M., de Araújo, R. A., & Silva, M. J. B. (2022) · ecancermedicalscience · doi:10.3332/ecancer.2022.1382
Migraine and Risk of Breast Cancer: A Systematic Review and Meta-AnalysisPreprint
Peng, C., Wu, K., Chen, X., Gao, L., Li, C., Ge, W., He, L., & Chen, N. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4159246
Concomitant administration of warfarin and toremifene: A case report
Peng, W., Wang, Y., Zhang, Y., & Yang, L. (2022) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.13815
Prevention of Osteoporosis in Patients With Breast Cancer Treated With Aromatase Inhibitor Combined With Calcium/Vitamin D Supplements
Yang, S., Park, K., Kim, M., Jang, W. S., Song, B., Keum, H., Kang, B., & Lee, J. (2022) · Journal of Breast Disease · doi:10.14449/jbd.2022.10.2.61 · Cited by 2
The Relationship between PIK3CA Mutation and Hormone Receptor Positive and HER2 Negative Breast Cancer
依合里曼, ·. (2023) · Advances in Clinical Medicine · doi:10.12677/acm.2023.132384
Clinicopathological features and prognostic analysis of Her-2-negative breast mucinous adenocarcinoma: A SEER database analysisPreprint
Liang, X., Xu, Q., Wu, Z., & Zhang, H. (2023) · Research Square · doi:10.21203/rs.3.rs-2723855/v1
Targeted therapy
De, S. K. (2023) · Elsevier eBooks · doi:10.1016/b978-0-443-13312-1.00002-7
Neoadjuvant Chemo-Endocrine Therapy for Hormone Receptor Positive Breast Cancer: A Meta-Analysis
Li, Z., Dong, Y.-L., Cao, X.-Z., Ren, S.-S., & Zhang, Z. (2023) · Clinical and Experimental Obstetrics & Gynecology · doi:10.31083/j.ceog5004074
Avaliação de quimiocinas circulantes em pacientes com câncer de mama, o ardiloso luminal b e as misteriosas quimiocinas
Araújo, R. (2023) · doi:10.14393/ufu.te.2022.586
Amino-Modified Magnetic Nanoparticles Used in Exploring the Mechanism of CCL18-Induced H19 Upregulation that Promotes Breast Cancer Cell Invasion by Regulating the EZH2-Mediated Repression of E-Cadherin Expression
Jia, H., Sun, R., Jia, W., Hu, Y., Gu, R., Dong, J., & Tang, K. (2023) · Journal of Biomedical Nanotechnology · doi:10.1166/jbn.2023.3538
CircPGPEP1 promotes the growth and metastasis of breast cancer cells by targeting miR-30b
Tan, Y., & Wang, X. (2023) · Molecular & Cellular Toxicology · doi:10.1007/s13273-023-00376-9
Neoadjuvant immunotherapy in early-stage triple negative breast cancer
Laouris, P., Rodrigues, M. E. S., da Costa, S. C. V., & de Paula, B. (2023) · Annals of Translational Medicine · doi:10.21037/atm-23-1550
Development of a prognostic nomogram for lymph node positive HR+/HER2– breast cancer patients: a study of SEER database and a Chinese cohort
Cheng, X., Jiang, J., Liang, X., & Zheng, X. (2023) · Gland Surgery · doi:10.21037/gs-23-177
Hormone-dependent cancers
Kumar, R. A., & McEwan, I. J. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-91141-2.00005-2
Novel Gene Signatures Predictive of Patient Recurrence-free Survival in HR+HER2- Breast CancerPreprint
Jin, M., Jin, X., & Shao, Z. (2024) · Research Square · doi:10.21203/rs.3.rs-3930524/v1
Causal associations between fibroblast growth factors and breast cancer: evidence from two-sample Mendelian randomization analysisPreprint
Feng, F., Sun, M., Yao, Y., Li, H., Song, L., & Sun, C. (2024) · Research Square · doi:10.21203/rs.3.rs-5367392/v1
Convergent Strategy to Synthesize (S)-8-(4-((1-(3-Fluoropropyl)-pyrrolidin-3-yl)oxy)phenyl)-7-(4-hydroxyphenyl)-5,6-dihydronaphthalen-2-ol as a Selective Estrogen Receptor Degrader
Chen, P., Feng, X., Lu, Z., & Li, T. (2024) · Chinese Journal of Organic Chemistry · doi:10.6023/cjoc202403009
Neoadjuvant chemotherapy and pathological complete response in hormone-positive HER2-negative breast cancer: influence of progesterone receptor expression, tumor grade and Ki-67
Алексеевна, З. Е., Болотина, Л. В., Rasskazova, E. A., Нодарович, С. В., Максимов, К. В., & Зикиряходжаев, А. Д. (2025) · MD-Onco · doi:10.17650/2782-3202-2024-4-4-41-46
Molecular Characterisation of the Residual Disease after Neoadjuvant Endocrine Therapy in Er+/Her2- Breast Cancer Uncovers Biomarkers of Tumour ResponsePreprint
López-Velazco, J. I., Manzano, S., Elorriaga, K., Otaño, M., Lahuerta, A., Álvarez, L., Etxabe, I., Huarte, M., Buch, E., Giménez, J., et al. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5218750
Palbociclib: randomisierte Studien und Real-World-Evidenz als Grundlage für die Therapieplanung beim metastasierten Mammakarzinom
Ruckhäberle, E., Schmidt, M., Welt, A., Harbeck, N., Wöckel, A., Gluz, O., Park‐Simon, T., Untch, M., & Lux, M. P. (2025) · Senologie - Zeitschrift für Mammadiagnostik und -therapie · doi:10.1055/a-2579-9530
Circulating chemokines and leukocytes and their impact on breast cancer prognosis
de Araújo, R. A., da Luz, F. A. C., Marinho, E. D. C., Nascimento, C. P., da Silva, A. C. A. L., Monteiro, M. L. G. D. R., & Silva, M. J. B. (2025) · Discover Oncology · doi:10.1007/s12672-025-02881-w
Genomic landscape of estrogen receptor-positive HER2-negative advanced breast cancer with acquired resistance to aromatase inhibitors: Identification of an ESR1 alteration-related gene signature
Barraud, S., Vacher, S., Schiffler, C., Wong, J., Hamza, A., Courtois, L., Pinton, A., Servant, N., Baulande, S., Attignon, V., et al. (2025) · British Journal of Cancer · doi:10.1038/s41416-025-03083-5
Study protocol to assess clinical outcomes of breast cancer and its relationship with access to healthcare in Brazil—BREAST trial (BRaziLian outcomE for metAStatic breasT cancer): a prospective observational study in HER2-negative/hormone receptor-positive metastatic disease
Sanvido, V. M., Pontes, L. D. B., Machado, R. H., Gomes, J. O., Barbante, L. G., Nicola, M. L., Tokunaga, S. M., Miranda, T. A., Laranjeira, L. N., Negrelli, K. L., et al. (2025) · BMJ Open · doi:10.1136/bmjopen-2024-087877
Roles of Zinc and Zinc Transporters in Breast Cancer
Takatani‐Nakase, T., Matsui, C., Sakitani, M., Nakao, K., & Nakase, I. (2025) · Royal Society of Chemistry eBooks · doi:10.1039/9781837676583-00245
Palliative care use and end-of-life care quality in HR+/HER2- metastatic breast cancer
Cohn, J. G., Locke, S. C., Herring, K. W., Dent, S. F., & LeBlanc, T. W. (2025) · Breast Cancer Research and Treatment · doi:10.1007/s10549-025-07805-4
Targeting the ERα DBD–LBD Interface with Mitoxantrone Disrupts Receptor Function through Proteasomal Degradation
Wang, H., Luo, Y., Artham, S., Wang, Q., Peng, Y., Yun, Z., Li, X., Wu, C., Liu, Z., Weber-Bonk, K. L., et al. (2025) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-25-0405
Association of hormone replacement therapy and image-detected breast cancer
BURKE, H. B. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1647152
Theranostic application of extracellular vesicles in breast cancer
Gharavi, A. T., Mehrabi, Z., Qasempouri, S. N., Hanjani, N. A., Saffari, N., & Salimi, M. (2025) · Current topics in membranes · doi:10.1016/bs.ctm.2025.07.006
Strategies for Treating Sexual Health Concerns After Breast and Gynecologic Cancer
Mihulka, O., Curran, M., Narasimhan, R. M., Moore, J. F., & Rojas, K. E. (2025) · Journal of Minimally Invasive Gynecology · doi:10.1016/j.jmig.2025.12.021
Additional file 1 of Photothermal hydrogel platform for prevention of post-surgical tumor recurrence and improving breast reconstruction
Yang, X., Gao, L., Wei, Y., Tan, B., Wu, Y., Yi, C., & Liao, J. (2021) · Figshare · doi:10.6084/m9.figshare.16767611
Additional file 5 of Photothermal hydrogel platform for prevention of post-surgical tumor recurrence and improving breast reconstruction
Yang, X., Gao, L., Wei, Y., Tan, B., Wu, Y., Yi, C., & Liao, J. (2021) · Figshare · doi:10.6084/m9.figshare.16767623
Additional file 1 of A prospective study on tumour response assessment methods after neoadjuvant endocrine therapy in early oestrogen receptor-positive breast cancer
López-Velazco, J. I., Manzano, S., Otaño, M., Elorriaga, K., Bultó, N., Herrero, J. J., Lahuerta, A., Segur, V., Álvarez-López, I., Caffarel, M. M., et al. (2024) · Figshare · doi:10.6084/m9.figshare.24940553
Additional file 4 of Photothermal hydrogel platform for prevention of post-surgical tumor recurrence and improving breast reconstruction
Yang, X., Gao, L., Wei, Y., Tan, B., Wu, Y., Yi, C., & Liao, J. (2021) · Figshare · doi:10.6084/m9.figshare.16767620
Additional file 6 of Photothermal hydrogel platform for prevention of post-surgical tumor recurrence and improving breast reconstruction
Yang, X., Gao, L., Wei, Y., Tan, B., Wu, Y., Yi, C., & Liao, J. (2021) · Figshare · doi:10.6084/m9.figshare.16767626
Additional file 7 of Photothermal hydrogel platform for prevention of post-surgical tumor recurrence and improving breast reconstruction
Yang, X., Gao, L., Wei, Y., Tan, B., Wu, Y., Yi, C., & Liao, J. (2021) · Figshare · doi:10.6084/m9.figshare.16767629
Additional file 2 of SCR-6852, an oral and highly brain-penetrating estrogen receptor degrader (SERD), effectively shrinks tumors both in intracranial and subcutaneous ER + breast cancer models
Zhou, F., Yang, G., Xue, L., Liu, Y., Guo, Y., Zhu, J., Yuan, L., Gu, P., Tang, F., Shan, J., et al. (2023) · Figshare · doi:10.6084/m9.figshare.23949852
Additional file 1 of SCR-6852, an oral and highly brain-penetrating estrogen receptor degrader (SERD), effectively shrinks tumors both in intracranial and subcutaneous ER + breast cancer models
Zhou, F., Yang, G., Xue, L., Liu, Y., Guo, Y., Zhu, J., Yuan, L., Gu, P., Tang, F., Shan, J., et al. (2023) · Figshare · doi:10.6084/m9.figshare.23949849
Additional file 3 of SCR-6852, an oral and highly brain-penetrating estrogen receptor degrader (SERD), effectively shrinks tumors both in intracranial and subcutaneous ER + breast cancer models
Zhou, F., Yang, G., Xue, L., Liu, Y., Guo, Y., Zhu, J., Yuan, L., Gu, P., Tang, F., Shan, J., et al. (2023) · Figshare · doi:10.6084/m9.figshare.23949855
Additional file 2 of Photothermal hydrogel platform for prevention of post-surgical tumor recurrence and improving breast reconstruction
Yang, X., Gao, L., Wei, Y., Tan, B., Wu, Y., Yi, C., & Liao, J. (2021) · Figshare · doi:10.6084/m9.figshare.16767614
Additional file 3 of Photothermal hydrogel platform for prevention of post-surgical tumor recurrence and improving breast reconstruction
Yang, X., Gao, L., Wei, Y., Tan, B., Wu, Y., Yi, C., & Liao, J. (2021) · Figshare · doi:10.6084/m9.figshare.16767617
Additional file 1 of Claudin-4-adhesion signaling drives breast cancer metabolism and progression via liver X receptor β
Murakami-Nishimagi, Y., Sugimoto, K., Kobayashi, M., Tachibana, K., Kojima, M., Okano, M., Hashimoto, Y., Saji, S., Ohtake, T., & Chiba, H. (2024) · Figshare · doi:10.6084/m9.figshare.26582348
Additional file 1 of The PTX3/TLR4 autocrine loop as a novel therapeutic target in triple negative breast cancer
Giacomini, A., Turati, M., Grillo, E., Rezzola, S., Ghedini, G. C., Schuind, A. C., Foglio, E., Maccarinelli, F., Faletti, J., Filiberti, S., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26619532
Unmasking the double agent in breast cancer: how ESRRA drives tumor growth and facilitates immune evasion?
Zheng, Z.-Z., Chen, L., Hu, G.-S., Peng, B.-L., Huang, Q.-X., Wang, A., Du, S.-Y., Wang, C., & Liu, W. (2025) · Chinese Science Bulletin (Chinese Version) · doi:10.1360/csb-2025-5682
Integrated bulk RNA and single-cell RNA sequencing to identify and validate exercise-related genes for predicting the prognosis of invasive ductal carcinomaPreprint
Tang, Y., Zhang, P. K., Yuan, Y., & Gao, J. (2026) · Research Square · doi:10.21203/rs.3.rs-8444169/v1
Insights from Genomic Sequencing of Preclinical Breast Cancer Models Establish Human Parallels to Increase Therapeutic Applicability
Schulte, A., & Andrechek, E. R. (2026) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1007/s10911-026-09599-7 · Cited by 1
Defining prognostic subgroups and treatment outcomes in estrogen receptor low-positive de novo metastatic breast cancer
Klugman, M. F., Aboumrad, M., Chen, R., Marshall, C. H., Canzoniero, J. V., Wolff, A. C., & Visvanathan, K. (2026) · Breast Cancer Research and Treatment · doi:10.1007/s10549-025-07872-7
Uptake Patterns of [18F]Fluoroestradiol PET/MRI in Benign Breast Lesions and Molecular Breast Cancer Subtypes
Spiegel, T., Rasul, S., Pötsch, N., Stiglbauer-Tscholakoff, A., Kapetas, P., Nics, L., Gebhart, P., Rausch, I., Bagó-Horváth, Z., Clauser, P., et al. (2026) · Cancers · doi:10.3390/cancers18040696
A machine learning assay to predict disease recurrence in hormone receptor-positive breast cancer
Bielo, L. B., Trapani, D., Razavi, P., Chandarlapaty, S., Zhan, Y., & Curigliano, G. (2026) · ESMO Open · doi:10.1016/j.esmoop.2026.106064
TonEBP regulates ESR1 transcription and ER-dependent proliferation in ER-positive breast cancer
Kang, H. J., Song, H., Park, H., Park, H., Shin, G. W., Son, K. S., Jeong, Y., Ko, S. H. N. S. T., Nam, D., Kwon, H. M., et al. (2026) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2026.153559
Chemotherapy Declination Among Patients With Early-Stage Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer and High Oncotype DX Recurrence Scores
Jackson, I. N., Lei, X. J., Sullivan, M. P., Barcenas, C. H., Giordano, S. H., & Chávez‐MacGregor, M. (2026) · JCO Oncology Practice · doi:10.1200/op-25-01106
Adjuvant endocrine therapy in estrogen-low breast cancer in the era of CDKI: are we at another uncertain crossroads?
Valerio, M. R., Scandurra, G., Greco, M., Mesi, C., Gebbia, V., & Sambataro, D. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1636348
Prevalence and Prognostic Implications of Circulating Tumor Cells Among Patients Undergoing Neoadjuvant Chemotherapy for Early-Stage Breast Cancer
Freeman, M., Seńkowska, A. P., Chehade, R., Compaore, S., Caro, G. D., Hartmann, N., WENSTRUP, R. J., Lohmann, A. E., Tran, W. T., & Jerzak, K. J. (2026) · Clinical Breast Cancer · doi:10.1016/j.clbc.2026.05.005
РЕВЕРС ДО НЕОАД’ЮВАНТНОЇ ЕНДОКРИННОЇ ТЕРАПІЇ (НЕТ) В ПРОЦЕСІ НЕОАД’ЮВАНТНОЇ ХІМІОТЕРАПІЇ (НХТ) У ХВОРИХ НА ER-ПОЗИТИВНИЙ HER-2/NEU НЕГАТИВНИЙ РАННІЙ РАК МОЛОЧНОЇ ЗАЛОЗИ
Cheshuk, V., & Малець, М. (2026) · Actual Problems of Nephrology · doi:10.37321/nefrology.2025.36-37-07
Menopause in Cancer Survivors
Minkin, M. J., Larkin, L. C., & Lustberg, M. B. (2026) · Obstetrics and Gynecology Clinics of North America · doi:10.1016/j.ogc.2026.04.004
CAFs and Endocrine Therapy Resistance in Hormone Receptor-Positive Breast Cancer
Sofianidi, A. A., Stafyla, V. K., & Zagouri, F. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27104633
Oral selective estrogen receptor degraders (SERDs) for the treatment of hormone receptor-positive, HER2-negative breast cancer title
Etessami, J. D., Valenza, C., Giachetti, P. P. M. B., Crimini, E., Ferraro, E., Marra, A., Belli, C., Minchella, I., Zagami, P., Curigliano, G., et al. (2026) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2026.2678481
Adenocarcinoma of anogenital mammary-like glands: a rare primary vulvar tumour
Aguiar, R. S., Teves, M., Morgado, D., Carneiro, V., & Maciel, N. (2026) · BMJ Case Reports · doi:10.1136/bcr-2026-272510
Efficacy and Toxicity of CDK4/6 Inhibitors in Early and Metastatic HR+/HER2− Breast Cancer: An Updated Meta-Analysis of Phase III Trials
Dhanoa, R. K., Thapa, S., Kancharla, P., & Kurian, S. (2026) · Cancers · doi:10.3390/cancers18111714
Tamoxifen Modulates Actin Stress Fibre Dynamics Through c‐Src—MLCK Signalling in Breast Cancer Cells
Biswas, B., Ahmed, S., Manickavasagan, S., Chaudhari, A. J., & Selvaraju, S. (2026) · Cell Biology International · doi:10.1002/cbin.70169
A Real-World Study on the Effectiveness and Safety of Elacestrant in Patients with ESR1-Mutated Metastatic Breast Cancer Progressing After CDK4/6 Inhibitors and Endocrine Therapy
Greco, M., Gebbia, V., Berardi, R., Usset, A., Ricciardi, G. R. R., Verde, N. M. L., Sanò, M. V., Martorana, F., Staropoli, N., Pernice, G., et al. (2026) · Cancers · doi:10.3390/cancers18132042
HER2 assessment in urothelial carcinoma: standardization challenges and the path forward
Xie, P. Y., Wang, Y., Lu, L., Chen, J., Wei, J., Huang, Y., Guo, C., Li, J., Yan, X., Guo, J., et al. (2026) · Cancer and Metastasis Reviews · doi:10.1007/s10555-026-10353-y
Transcription Factors in Breast Cancer Oncogenesis and Progression
Fiore, L., Li, Z., Montgomery, C., Coleman, A., Kenny, C., & Weigel, R. J. (2026) · Molecular and Cellular Biology · doi:10.1080/10985549.2026.2694520
Assessing the risk of adverse drug events from combining aromatase inhibitors with CDK4/6 inhibitors using the FAERS and JADER databases
Fan, Z., Sun, P., & Li, L. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1823079
Latin American consensus on the medical oncologic management of early-stage HR+/HER2− breast cancer: Addressing regional disparities in Spanish-speaking countries
Landaverde, D., Petracci, F. E., de Oro., Á. G., Bravo-Garzón, M. A., Estévez, M., Arce-Salinas, C., González, I., Véliz, I., Amador, J. L., Castillo, O., et al. (2026) · The Breast · doi:10.1016/j.breast.2026.104865
Surgical Decision-Making and Treatment Response in Invasive Lobular Carcinoma Treated with Primary Surgery or Neoadjuvant TherapyPreprint
Riis, M. L. H., Arozamena, C. C., Lømo, J., Lingjærde, O. C., & Norum, J. H. (2026) · Research Square · doi:10.21203/rs.3.rs-9879050/v1
Pharmacological chromatin remodeling enhances response to estrogen therapy in ER + breast cancer
Thomas, A. L. J., Karakyriakou, B., Muskus, P. C., Roberts, A. M., Rendleman, J., Warren, A., Lu, H., Birmingham, K. A., Friedman, M. K., Goen, A. E., et al. (2026) · Molecular Oncology · doi:10.1002/1878-0261.70307
Adiposity Excess and Vertebral Fractures in Patients With Breast Cancer Taking Aromatase Inhibitors
Schivardi, G., Cosentini, D., Scartabellati, G., Ravanelli, M., Moretti, L., Mazziotti, G., Bazzoli, M., Strazzeri, S., Delbarba, A., Grisanti, S., et al. (2026) · JAMA Network Open · doi:10.1001/jamanetworkopen.2026.26450
Dynamic circulating tumor DNA profiling of ESR1 mutations in HR+/HER2− advanced breast cancer: from prognostic biomarker to clinical decision-making – a comprehensive review
Ren, S., Li, P., Zhu, D., Zhao, L., & Zhang, X. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1881097

Authors: Burstein, H. J.
Affiliations: Brigham and Women's Hospital (US)
Corresponding author: Burstein, Harold J.
ORCID: Burstein, Harold J.
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2020-12-24
Volume: 383
Issue: 26
Pages: 2557-2570
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmra1307118
OpenAlex: W3116128628
Cited by: 316
References: 106
Citations by year: 2026: 51 · 2025: 53 · 2024: 67 · 2023: 62 · 2022: 53 · 2021: 30
FWCI: 3.70
Type: journal article
Language: en
Open access: closed
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
Keywords: estrogen receptor-positive breast cancer, HER2-negative breast cancer, systemic therapy, antiestrogen therapy, breast cancer heterogeneity, progesterone receptor expression, tumor grade
MeSH terms: Breast Neoplasms, Female, Humans, Prognosis, Receptors, Estrogen, Chemotherapy, Adjuvant, Erb-b2 Receptor Tyrosine Kinases, Receptor, ErbB-2, Neoadjuvant Therapy, Selective Estrogen Receptor Modulators, Estrogen Receptor Antagonists

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Systemic Therapy for Estrogen Receptor–Positive, HER2-Negative Breast Cancer

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks